The Science of Drug Development: Lessons from a Pioneer in Pharmaceutical Decision-Making

Jay Andersen, a pioneer in pharmaceutical decision-making, shared some lessons learned from developing portfolio management and probability assessment approaches.
Biopharma BD&L: the tsunami is upon us

Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future. As the biopharma industry navigates an increasingly complex marketplace, traditional approaches to identifying and evaluating potential drug candidates are showing signs of strain.
Pharma portfolio analytics in a gen AI world

I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in.
Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD

Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
The Great Disruption: how Chinese assets will reshape drug development

Chinese biopharma companies are at an inflection point, with rapidly advancing in science, know-how, + talent. Chinese assets are poised to reshape drug development.
5 insights from JPM 2025

Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
AI for biopharma business development: finding the right assets faster

By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions.
Biotech Limited Partners: learnings from investing in biotech venture capital funds

Limited Partners (LPs) are at the heart of the biotech funding ecosystem—these crucial players ignite the funding flywheel that drives biotech innovation.
Enabling every cure for community matters: Our AI-powered journey

As we move through 2024, I’m thrilled with the extraordinary work our team is doing to change how we finance drug development: from funding next-generation therapies to helping others identify the highest potential cures in their development pipelines.